- Home
- VYGR vs NETD Comparison
VYGR vs NETD Comparison
Compare VYGR & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- NETD
- Stock Information
- Founded
- VYGR 2013
- NETD 2023
- Country
- VYGR United States
- NETD United States
- Employees
- VYGR N/A
- NETD N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- VYGR Health Care
- NETD
- Exchange
- VYGR Nasdaq
- NETD Nasdaq
- Market Cap
- VYGR 342.5M
- NETD 409.1M
- IPO Year
- VYGR 2015
- NETD 2023
- Fundamental
- Price
- VYGR $5.75
- NETD $10.78
- Analyst Decision
- VYGR Strong Buy
- NETD
- Analyst Count
- VYGR 9
- NETD 0
- Target Price
- VYGR $16.44
- NETD N/A
- AVG Volume (30 Days)
- VYGR 485.6K
- NETD 29.9K
- Earning Date
- VYGR 11-12-2024
- NETD 01-01-0001
- Dividend Yield
- VYGR N/A
- NETD N/A
- EPS Growth
- VYGR N/A
- NETD N/A
- EPS
- VYGR 0.47
- NETD 0.45
- Revenue
- VYGR $163,784,000.00
- NETD N/A
- Revenue This Year
- VYGR N/A
- NETD N/A
- Revenue Next Year
- VYGR N/A
- NETD N/A
- P/E Ratio
- VYGR $12.33
- NETD $23.99
- Revenue Growth
- VYGR 3.40
- NETD N/A
- 52 Week Low
- VYGR $5.19
- NETD $10.37
- 52 Week High
- VYGR $11.72
- NETD $10.80
- Technical
- Relative Strength Index (RSI)
- VYGR 41.30
- NETD 69.24
- Support Level
- VYGR $6.08
- NETD $10.77
- Resistance Level
- VYGR $6.55
- NETD $10.80
- Average True Range (ATR)
- VYGR 0.35
- NETD 0.01
- MACD
- VYGR -0.05
- NETD 0.00
- Stochastic Oscillator
- VYGR 14.51
- NETD 71.43
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.